These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 10952595)
21. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus]. Cetinkaya E; Coban AY; Durupinar B Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076 [TBL] [Abstract][Full Text] [Related]
22. Effect of quinolones against slowly growing bacteria. Dalhoff A; Matutat S; Ullmann U Chemotherapy; 1995; 41(2):92-9. PubMed ID: 7758362 [TBL] [Abstract][Full Text] [Related]
23. Antimicrobial activity of carbene complexes of rhodium(I) and ruthenium(II). Cetinkaya B; Cetinkaya E; Küçükbay H; Durmaz R Arzneimittelforschung; 1996 Aug; 46(8):821-3. PubMed ID: 9125286 [TBL] [Abstract][Full Text] [Related]
24. Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group. Jones RN; Reller LB; Rosati LA; Erwin ME; Sanchez ML Diagn Microbiol Infect Dis; 1992 Jul; 15(5):425-34. PubMed ID: 1643819 [TBL] [Abstract][Full Text] [Related]
25. Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. Eliopoulos GM; Wennersten CB; Moellering RC Diagn Microbiol Infect Dis; 1996 May; 25(1):35-41. PubMed ID: 8831043 [TBL] [Abstract][Full Text] [Related]
26. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis. Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871 [TBL] [Abstract][Full Text] [Related]
27. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution]. Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Hirose T; Shigeta S; Yamaguti O; Ishibashi K; Suzutani T; Yoshida H; Imafuku Y; Murai M; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Sato S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Furuya N; Deguchi T; Ishihara S; Ooe H; Oka T; Kitamura M; Fukuhara Y; Kamidono S; Arakawa S; Kumon H; Monden K; Matsumoto T; Muratani T; Naito S; Egashira T; Konishi T; Kohno S; Hirakata Y; Kondo A; Matsuda J; Nakano M Jpn J Antibiot; 2006 Jun; 59(3):177-200. PubMed ID: 16913404 [TBL] [Abstract][Full Text] [Related]
28. Comparative in vitro activity of the new fluoroquinolone BMY-40062. Chin NX; Neu H Eur J Clin Microbiol Infect Dis; 1990 Aug; 9(8):620-4. PubMed ID: 2120060 [TBL] [Abstract][Full Text] [Related]
29. Propolis loaded liposomes: evaluation of antimicrobial and antioxidant activities. Aytekin AA; Tuncay Tanrıverdi S; Aydın Köse F; Kart D; Eroğlu İ; Özer Ö J Liposome Res; 2020 Jun; 30(2):107-116. PubMed ID: 30913939 [TBL] [Abstract][Full Text] [Related]
30. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution]. Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333 [TBL] [Abstract][Full Text] [Related]
31. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2002). III. Secular changes in susceptibility]. Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Hirose T; Yamaguti O; Ishibashi K; Shigeta S; Suzutani T; Yoshida H; Imafuku Y; Murai M; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Sato S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Furuya N; Deguchi T; Ishihara S; Ooe H; Nishikawa M; Oka T; Kitamura M; Fukuhara Y; Kamidono S; Arakawa S; Kumon H; Monden K; Matsumoto T; Takahashi K; Naito S; Egashira T; Kohno S; Miyazaki Y; Hirakata Y; Aoki S Jpn J Antibiot; 2004 Aug; 57(4):311-403. PubMed ID: 15535040 [TBL] [Abstract][Full Text] [Related]
32. In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study. Soussy CJ; Cluzel M; Ploy MC; Kitzis MD; Morel C; Bryskier A; Courvalin P J Antimicrob Chemother; 1999 Jun; 43 Suppl C():43-50. PubMed ID: 10404337 [TBL] [Abstract][Full Text] [Related]
33. Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin. Chaudhry AZ; Knapp CC; Sierra-Madero J; Washington JA Antimicrob Agents Chemother; 1990 Sep; 34(9):1843-5. PubMed ID: 2285304 [TBL] [Abstract][Full Text] [Related]
34. Ofloxacin loaded gellan/PVA nanofibers - Synthesis, characterization and evaluation of their gastroretentive/mucoadhesive drug delivery potential. Vashisth P; Raghuwanshi N; Srivastava AK; Singh H; Nagar H; Pruthi V Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():611-619. PubMed ID: 27987752 [TBL] [Abstract][Full Text] [Related]